Journal
CLINICAL CANCER RESEARCH
Volume 25, Issue 4, Pages 1130-1132Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-2509
Keywords
-
Categories
Funding
- Cancer Research UK (CRUK) [C36463/A22246, C36463/A20764]
- National Institute for Health Research (NIHR) [167097]
Ask authors/readers for more resources
Despite a number of preclinical studies demonstrating that the activity of anti-CTLA-4 antibodies in murine models of cancer relies on effector T-cell activation and regulatory T cell depletion, the activity of the clinical antibodies remains controversial. To decipher such mechanisms is critical to the development of novel and more potent immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available